Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
about
Nomograms in oncology: more than meets the eyeKallikreins as biomarkers for prostate cancerNotch signaling in prostate cancer: a moving targetRationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerFocal therapy in prostate cancer: the current situationEffect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical ProstatectomyIdentification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMTMate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer.Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.Inherited genetic variant predisposes to aggressive but not indolent prostate cancer.Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer.Adjuvant medical therapy for prostate cancer.Predicting 15-year prostate cancer specific mortality after radical prostatectomy.Gene expression pathways of high grade localized prostate cancer.Recurrent prostate cancer genomic alterations predict response to brachytherapy treatmentValidation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.Prognostic models to predict overall and cause-specific survival for patients with middle ear cancer: a population-based analysis.Validation study of a web-based assessment of functional recovery after radical prostatectomyInterpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.Supervised regularized canonical correlation analysis: integrating histologic and proteomic measurements for predicting biochemical recurrence following prostate surgeryRadiation therapy in prostate cancer: a risk-adapted strategy.Pre-treatment risk stratification of prostate cancer patients: A critical review.Current status of radical prostatectomy for high-risk prostate cancer.Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens.Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values.Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05)A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomyLong-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancerEffect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgeryA contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomyPrediction of prostate cancer recurrence using quantitative phase imagingOncologic outcomes of surgery in t3 prostate cancer: experience of a single tertiary centerHigh-risk prostate cancer-classification and therapy.The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia.PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.Melanoma-specific mortality and competing mortality in patients with non-metastatic malignant melanoma: a population-based analysis.Tissue biomarkers for prostate cancer radiation therapy.Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database.Population-based study of long-term functional outcomes after prostate cancer treatment.
P2860
Q26830260-EF1E6407-C813-49C7-8475-EA7D6B2CDFB2Q26862434-FDFD66E6-6C8C-4AD5-AE50-47BBC039A6F4Q27001047-A914D6E0-CF21-417C-AC76-FB5DC03091EFQ27028084-F3AD6CDD-640A-45BD-97E8-211219F5B01FQ28242346-1233A43E-4DD5-4DCC-AA2A-3AA74466EABBQ28554583-75765940-14D4-48C7-B860-2272D174A514Q28744173-EF7B16C9-3E2D-4B99-B32B-9D446B57BE4AQ31092851-ED11F47C-84D7-4F84-81E1-536E4CAD5D4BQ33631383-2086F2B0-7CE7-4342-9B6E-860C688B431EQ33719967-8B020688-ABF5-4B0F-969F-08A8E770E14CQ33745069-0C6BCC95-65E4-452E-838D-3656C5A6A4ADQ33758771-4709C1AD-1646-44A2-A02D-AFDF9780BC87Q33759725-7643A929-F7C8-480E-B33E-5CE8413E7D58Q33832517-E4BA4E56-3F52-4E9D-915C-F1527FB14200Q33852664-CDE228AE-4C11-4A84-A17B-4276F38DA66EQ33898869-97BA7C9F-2940-47B3-B09C-632FEAA34609Q33993472-426337FE-6C6B-4FBF-9D16-AF91579E3F27Q34029623-D9CD49EA-F486-4447-B81F-3705B160DB44Q34081632-304A19F7-8A88-4760-9EB7-4419E8BE18BEQ34086557-19A47D7A-EC11-44AC-A1E2-F30AA786F38EQ34105674-F40939E1-235F-42BA-B5A5-FA21BE46291BQ34111590-AC579524-3C2E-4B96-881F-135BDF7689A0Q34268868-2EA4784C-DCA8-45F4-AD38-F4DB29F4D0FAQ34346841-89743C5B-D8B6-4599-938A-6D9593B5E38EQ34756267-D5602ADD-2ABA-4D25-A2A5-8C1837DC5A91Q35022732-E44ED14F-2E9B-44B5-B4CB-BA78EB0F8921Q35095184-3A2AB092-2E50-49BA-BAFE-0D8300FA5D5AQ35096149-AE912887-C1FA-4BD6-A28E-A262558D7067Q35115736-8332B5C0-9A4C-41AA-BB24-E7B06125C990Q35211723-76F5D584-830D-4E92-9E93-2C59F1818ECEQ35322697-7F977713-2D6F-4B55-B1C8-3FBA25888432Q35608187-4DBF54A0-5306-4D7C-BCB6-C11BCE85C4CFQ35642310-A5E8EE4B-F360-4141-9A8A-840FDF89694EQ35869811-EF43D684-EA0E-4335-B684-14DFCC55A112Q35894629-53067B08-6800-4D1F-A190-32CD8EE4F1D3Q36033729-B886EB92-1808-48E0-A9E2-FDE0DDB12C6FQ36070403-D4E2243E-0A7D-4966-898A-DC7F011328ECQ36141341-6A7B18CB-81B2-43D2-9436-91E25A271F29Q36199750-7C1DAD2A-6261-40A8-B36E-075588941C3BQ36260481-F83DEAB5-1FB1-4F7E-83A0-C5E60A13B6CD
P2860
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Prostate cancer-specific morta ...... prostate-specific antigen era.
@en
type
label
Prostate cancer-specific morta ...... prostate-specific antigen era.
@en
prefLabel
Prostate cancer-specific morta ...... prostate-specific antigen era.
@en
P2093
P2860
P356
P1476
Prostate cancer-specific morta ...... prostate-specific antigen era.
@en
P2093
Andrew J Stephenson
David P Wood
Eric A Klein
Fernando J Bianco
James A Eastham
Michael W Kattan
Ofer Yossepowitch
Peter T Scardino
P2860
P304
P356
10.1200/JCO.2008.18.2501
P407
P577
2009-07-27T00:00:00Z